X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (935) 935
Newsletter (131) 131
Publication (60) 60
Newspaper Article (36) 36
Book Review (14) 14
Book Chapter (11) 11
Magazine Article (6) 6
Trade Publication Article (3) 3
Conference Proceeding (2) 2
Dissertation (2) 2
Transcript (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
tofacitinib (1008) 1008
index medicus (490) 490
humans (399) 399
rheumatoid arthritis (328) 328
rheumatology (210) 210
arthritis (204) 204
methotrexate (193) 193
janus kinase inhibitor (176) 176
inadequate response (170) 170
male (167) 167
female (164) 164
drug therapy (157) 157
double-blind (151) 151
care and treatment (150) 150
pharmacology & pharmacy (147) 147
rheumatoid factor (147) 147
efficacy (141) 141
safety (139) 139
pyrimidines - therapeutic use (138) 138
pyrroles - therapeutic use (138) 138
arthritis, rheumatoid - drug therapy (137) 137
dermatology (133) 133
middle aged (132) 132
jak inhibitor (127) 127
treatment outcome (127) 127
psoriasis (125) 125
piperidines - therapeutic use (123) 123
adult (122) 122
janus kinase (122) 122
placebo (122) 122
analysis (120) 120
research (120) 120
rheumatoid-arthritis (120) 120
protein kinase inhibitors - therapeutic use (116) 116
medical research (111) 111
adalimumab (107) 107
medicine, experimental (106) 106
animals (102) 102
dosage and administration (100) 100
janus kinases - antagonists & inhibitors (95) 95
ulcerative colitis (95) 95
cp-690,550 (94) 94
cytokines (91) 91
clinical trials (86) 86
modifying antirheumatic drugs (86) 86
antirheumatic agents - therapeutic use (85) 85
immunology (84) 84
pharmaceutical industry (79) 79
pyrimidines - adverse effects (77) 77
pyrroles - adverse effects (77) 77
aged (76) 76
disease (73) 73
inflammation (69) 69
tofacitinib cp-690,550 (69) 69
active rheumatoid-arthritis (68) 68
pyrimidines - administration & dosage (68) 68
pyrroles - administration & dosage (68) 68
piperidines - adverse effects (65) 65
patients (64) 64
protein kinase inhibitors - pharmacology (64) 64
abridged index medicus (63) 63
antirheumatic agents (63) 63
kinases (63) 63
placebo-controlled trial (63) 63
therapy (63) 63
double-blind method (62) 62
inflammatory bowel disease (62) 62
jak inhibitors (61) 61
piperidines - administration & dosage (61) 61
immunotherapy (60) 60
janus kinase 3 - antagonists & inhibitors (60) 60
baricitinib (59) 59
psoriasis - drug therapy (59) 59
health aspects (57) 57
protein kinase inhibitors - adverse effects (57) 57
combination (56) 56
medicine & public health (56) 56
mutual fund industry (53) 53
protein kinase inhibitors - administration & dosage (53) 53
pyrimidines - pharmacology (53) 53
pyrroles - pharmacology (52) 52
antirheumatic agents - adverse effects (51) 51
ruxolitinib (51) 51
usage (51) 51
medicine, general & internal (49) 49
piperidines - pharmacology (49) 49
psoriatic arthritis (49) 49
signal transduction (49) 49
dose-response relationship, drug (48) 48
gastroenterology & hepatology (48) 48
antirheumatic agents - administration & dosage (47) 47
tumor necrosis factor-tnf (47) 47
atopic dermatitis (46) 46
severity of illness index (46) 46
alopecia areata (44) 44
pathogenesis (42) 42
trial (42) 42
ustekinumab (42) 42
administration, oral (41) 41
crohn's disease (41) 41
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1062) 1062
German (16) 16
Russian (13) 13
Korean (10) 10
Spanish (10) 10
Portuguese (3) 3
Czech (2) 2
French (2) 2
Japanese (2) 2
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


RHEUMATOLOGY, ISSN 1462-0324, 06/2019, Volume 58, Issue 6, pp. 1011 - 1015
Objectives. Some patients with cutaneous DM demonstrate incomplete responses to conventional therapy while some, including those with extra-cutaneous... 
treatment | dermatomyositis | RHEUMATOLOGY | tofacitinib
Journal Article
Clinical Gastroenterology and Hepatology, ISSN 1542-3565, 2014, Volume 12, Issue 9, pp. 1485 - e2
Background & Aims: Tofacitinib, an orally administered Janus kinase inhibitor, blocks signaling through γ-chain-containing cytokines (interleukins 2, 4, 7, 9,... 
Tofacitinib | Crohn's disease | Randomized control trial | CP-690,550
Journal Article
ARTHRITIS & RHEUMATOLOGY, ISSN 2326-5191, 10/2017, Volume 69, Issue 10, pp. 1917 - 1920
Journal Article
Dermatologic Therapy, ISSN 1396-0296, 07/2019, Volume 32, Issue 4, pp. e12933 - n/a
Journal Article
by Rao, DA
ARTHRITIS & RHEUMATOLOGY, ISSN 2326-5191, 12/2018, Volume 70, Issue 12, pp. 1897 - 1900
Journal Article
Dermatologic Therapy, ISSN 1396-0296, 05/2019, Volume 32, Issue 3, pp. e12844 - n/a
Journal Article
Nature Biotechnology, ISSN 1087-0156, 08/2019, Volume 37, Issue 10, pp. 1104 - 1105
A ten-year collaboration gives biotech giant Gilead first rights to all of Galapagos’s pipeline. 
Tofacitinib | Adalimumab | Biotechnology | Swallowing | Collaboration | Cooperation
Journal Article
Arthritis care & research, ISSN 2151-464X, 05/2019, Volume 71, Issue 10, pp. 1387 - 1395
The risk of cardiovascular (CV) disease is higher in patients with psoriatic arthritis (PsA) versus the general population. Tofacitinib is an oral Janus kinase... 
lipids | psoriatic arthritis | cardiovascular | safety | tofacitinib
Journal Article
by Mueller and Hasler and Popp and Mattow and Durmisi and Souza and Rubbert-Roth and Schulze-Koops and Kempis
Journal of Clinical Medicine, ISSN 2077-0383, 09/2019, Volume 8, Issue 10, p. 1548
: Introduction: Tofacitinib is an oral JAK inhibitor indicated for the treatment of rheumatoid arthritis (RA). The efficacy and safety of tofacitinib have been... 
rheumatoid arthritis | oral | tofacitinib
Journal Article
Dermatology, ISSN 1018-8665, 02/2019, Volume 235, Issue 2, pp. 130 - 136
Background: Alopecia areata (AA) is a common autoimmune disorder characterized by patchy hair loss. There are many treatments available for AA. However,... 
Research Article | Tofacitinib | Ruxolitinib | Alopecia areata | TRIAL | UNIVERSALIS | EFFICACY | VARIANTS | SAFETY | ORAL TOFACITINIB | ASSOCIATION | DERMATOLOGY
Journal Article
Zeitschrift fur Rheumatologie, ISSN 0340-1855, 12/2018, Volume 77, Issue 10, pp. 952 - 957
Journal Article
Journal of the European Academy of Dermatology and Venereology, ISSN 0926-9959, 05/2019, Volume 33, Issue 5, pp. 850 - 856
There have been a number of case reports and small clinical trials reporting promising outcomes of Janus Kinase ( JAK ) inhibitors tofacitinib, ruxolitinib and... 
UNIVERSALIS | INFECTIONS | TOPICAL RUXOLITINIB | VARIANTS | REGROWTH | ORAL TOFACITINIB | PATIENT | TREATED PATIENTS | ARTHRITIS | PSORIASIS | DERMATOLOGY | Alopecia | Tofacitinib | Baldness | Analysis
Journal Article
Journal of Dermatological Science, ISSN 0923-1811, 11/2018, Volume 92, Issue 2, pp. 218 - 220
Journal Article
Journal of immunology (Baltimore, Md. : 1950), ISSN 0022-1767, 7/2014, Volume 193, Issue 1, pp. 48 - 55
Immunogenicity remains the ‘Achilles’ heel’ of protein-based therapeutics. Anti-drug antibodies produced in response to protein therapeutics can severely limit... 
immunotoxin | Tofacitinib | CP690-550 | immunogenicity
Journal Article
Dermatologic Therapy, ISSN 1396-0296, 09/2019, Volume 32, Issue 5, p. n/a
Alopecia areata (AA) is a non‐scarring alopecia, which often carries a major impact on patients' quality of life. Currently there is no single approved... 
baricitinib | ruxolitinib | alopecia areata | JAK inhibitors | tofacitinib
Journal Article
Drugs, ISSN 0012-6667, 4/2017, Volume 77, Issue 5, pp. 521 - 546
The Janus kinase/signal transduction and activator of transcription (JAK–STAT) signaling pathway is implicated in the pathogenesis of inflammatory and... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | PHASE 2B TRIAL | VX-509 DECERNOTINIB | ALOPECIA-AREATA | MODIFYING ANTIRHEUMATIC DRUG | JANUS KINASE INHIBITOR | ACTIVE RHEUMATOID-ARTHRITIS | INADEQUATE RESPONSE | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | TOXICOLOGY | TOFACITINIB CP-690,550 | DRUG-DRUG INTERACTIONS | Janus Kinases - genetics | Humans | STAT Transcription Factors - metabolism | Janus Kinases - metabolism | Janus Kinases - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Inflammation - metabolism | STAT Transcription Factors - genetics | Signal Transduction - drug effects | Inflammation - drug therapy | Protein Kinase Inhibitors - therapeutic use | Protein Kinase Inhibitors - pharmacology | STAT Transcription Factors - antagonists & inhibitors | Autoimmune Diseases - metabolism | Autoimmune Diseases - drug therapy | Dosage and administration | Tofacitinib | Autoimmune diseases | Drug therapy | Regulatory agencies | Inflammatory bowel diseases | Phosphorylation | Transcription factors | Disease | Transcription | Pathogenesis | Genes | Disorders | Clinical trials | Intracellular signalling | Arthritis | Kinases | Inflammatory diseases | Signal transduction | Intestine | Rodents | Janus kinase | Tumor necrosis factor-TNF | Medical research | Cytokines | Psoriasis | Baldness | Immunodeficiency | Patients | Diseases | Reviews | Rheumatoid arthritis | Transduction | Intracellular | Mutation
Journal Article
Rheumatology, ISSN 1462-0324, 02/2019, Volume 58, Issue Supplement_1, pp. i17 - i26
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.